Mandate

Vinge acts for Medivir in connection with public offer

April 13, 2011

Vinge acts for Medivir in connection with the public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm) has announced a public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm). Vinge acts for Medivir.

Vinge’s team is headed by capital markets and public M&A partner Erik Sjöman and includes, among others, Christian Lindhé, Emil Hedberg, Jakob Warren and Markus Larsson. Göran Nyström (public M&A), Kristian Hugmark and Hanna Danwall (competition law) and Mattias Schömer and Maria Doeser (tax) are also on the team.

Related

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024

Vinge advises Polar Structure AB in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary

Vinge advises Polar Structure AB, a leading developer and owner of infrastructure, in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary. The proceeds will be used to finance the construction of a railway outside Boden, which will connect the existing iron ore line (Sw. Malmbanan) with H2 Green Steel’s new facility for large-scale production of green steel at Boden Industrial Park.
July 04, 2024

Vinge advises Bergs Timber AB (publ) and Bitus A

Vinge advises Bergs Timber AB (publ) and Bitus AB in connection with the divestment of the Fågelfors pellets business to J. Rettenmeier & Söhne. The Fågelfors pellets factory is based in Fågelfors in Högsby. The acquisition is subject to customary regulatory approvals.
July 03, 2024